What are the efficacy and functions of Delamanid/Delba?

Delamanid/Delamanid (Delamanid) is a new oral anti-tuberculosis drug, mainly for patients with multi-drug-resistant tuberculosis. It inhibits bacterial growth and spread by interfering with the biochemical reaction of nitro reduction in the cell wall of Mycobacterium tuberculosis, preventing the production of key lipids. This mechanism of action gives delamanid unique advantages in the treatment of multi-drug-resistant tuberculosis, especially for patients who have failed previous conventional treatments or are drug-resistant. Compared with traditional anti-tuberculosis drugs, delamanid can not only effectively control drug-resistant strains, but also delay the further development of drug resistance through combined drug regimens.

Delamanid is usually combined with other anti-tuberculosis drugs, such as rifampicin, isoniazid or aminoglycosides, to form a multi-drug regimen. The combined use not only improves treatment success but also maintains long-term efficacy in the context of drug-resistant strains. The drug is well absorbed after oral administration, but it must be taken strictly in accordance with the dosage and schedule instructed by the doctor to ensure stable blood concentration and achieve the best antibacterial effect.

Clinical observations show that delamanid has a rapid inhibitory effect on Mycobacterium tuberculosis, and its toxic and side effects are relatively controllable. Common reactions include mild gastrointestinal discomfort, mild liver function index abnormalities, or QT interval prolongation. During the treatment process, patients need to regularly monitor liver function, kidney function and electrocardiogram to detect abnormalities in time and adjust the medication plan. Patients should avoid increasing or decreasing the dosage of medication or stopping medication on their own to avoid affecting the therapeutic effect.

The clinical significance of delamanid lies not only in its significant antibacterial effect, but also in reducing the risk of drug resistance through combined treatment and improving the disease control rate of patients with multidrug-resistant tuberculosis. It has high safety and tolerability, and through standardized use, patients can obtain long-term, effective, and controllable therapeutic effects. In short, delamanid provides a scientific and precise treatment plan in the management of multi-drug-resistant tuberculosis, providing a new option for patient health and public health prevention and control.

Reference: https://go.drugbank.com/drugs/DB11637